| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10019173 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS10019323 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS10031044 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS10025139 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS10020261 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS10040464 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS20001928 | HPV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ADRA1A |
|---|---|
| DrugBank ID | DB00346 |
| Drug Name | Alfuzosin |
| Target ID | BE0000501 |
| UniProt ID | P35348 |
| Regulation Type | antagonist |
| PubMed IDs | 8799556; 12892027; 9122046; 15639685; 9223558; 8196478; 9870119; 16613526; 16553574; 11750253 |
| Citations | Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM: Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996 Jun;118(4):871-8.@@Lee M: Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. Am J Health Syst Pharm. 2003 Jul 15;60(14):1426-39.@@Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15.@@Lowe FC: Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 2004 Nov;26(11):1701-13.@@Martin DJ, Lluel P, Guillot E, Coste A, Jammes D, Angel I: Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther. 1997 Jul;282(1):228-35.@@Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D: Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci. 1994;54(21):1595-605.@@Beique L, Por CP, Evans MF: Are the new selective alpha-blockers better than non-selective alpha-blockers for benign prostatic hyperplasia? Can Fam Physician. 1998 Dec;44:2659-62.@@McVary KT: BPH: epidemiology and comorbidities. Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8.@@Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96.@@Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. |
| Groups | Approved; Investigational |
| Direct Classification | Quinazolinamines |
| SMILES | COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N(C)CCCNC(=O)C1CCCO1 |
| Pathways | |
| PharmGKB | PA164774795 |
| ChEMBL | CHEMBL709 |
